RecruitingNCT06655090

Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China

Studying Interstitial lung disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dai Huaping
Principal Investigator
Huaping Dai, M.D. Ph.D.
China-Japan Friendship Hospital
Enrollment
10000 target
Eligibility
All sexes
Timeline
2021 – 2027

Study locations (1)

Collaborators

The First Affiliated Hospital of Guangzhou Medical University · Nankai University · Jilin University · Shanghai Pulmonary Hospital, Shanghai, China · Shanghai Chest Hospital · Institute of Basic Medical Sciences CAMS · Tongji Hospital · National Institute for Occupational Health and Poison Control · Infervision Medical Technology Company Limited

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06655090 on ClinicalTrials.gov

Other trials for Interstitial lung disease

Additional recruiting or active studies for the same condition.

See all trials for Interstitial lung disease →

← Back to all trials